Sharechat Logo

AFT Pharmaceuticals now licensed in 124 countries worldwide

Thursday 20th July 2017

Text too small?

AFT Pharmaceuticals, which manufactures the Maxigesic painkiller, said it is now licensed in 124 countries worldwide after it inked a deal with a private European pharmaceutical company called Amicus SA Switzerland.

The agreement is for the licensing of its product line in three regions: the Baltics (Latvia, Estonia and Lithuania), Central Eastern Europe (Czech Republic, Hungary, Bulgaria, Romania and Slovakia) and most of the Balkans (Croatia, Slovenia, Serbia, Montenegro, Bosnia and Macedonia).

Maxigesic is currently sold in eight countries and "getting these agreements in place shows that we are expanding on our planned pathway to deliver on our sales targets," said chief executive Hartley Atkinson. 

Atkinson said Thursday some additional launches from the Amicus deal will take place within the closing period of the 2018 financial year.

The company had previously said it expects registration and product launches covering existing agreements to occur on a phased basis, with one-third in FY2018, one-quarter in both FY2019 and FY2020 and the balance in FY2021.

The company also said a deal inked in May with a French pharmaceutical company to out-license the product lien of Maxigesic to France, Monaco, Andorra and French dependencies was with Laboratoires Expanscience headquartered in Courbevoie, France. At the time, it was unable to disclose the name of the company. 

Atkinson also underscored that news that opioid derivatives would be added to France's list of prescription only medicines, will improve the sales prospects for codeine-free Maxigesic. 

AFT shares last traded at $2.35 and have dropped 26 percent in the past year. 


Bond Offer: Infratil Ltd, 7.2 year & 10.2 year unsecured unsubordinated bond

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

ANALYSIS: Should penalties for continuous disclosure breaches be relaxed?
Fletcher seeks urgent talks on Ihumatao stalemate
NZ economy grows 0.5% in June quarter, beating expectations
Restaurant Brands lifts 2Q sales; appetite for KFC offsets ditched Starbucks
Auckland jet fuel arrangements a potential barrier to new entrants
NZ dollar weaker after Fed split on outlook for further US cuts
Leading judge says court administration model 'outdated'
MARKET CLOSE: NZ shares fall; Goodman placement sees property stocks sold
NZ dollar eases as market eyes pending GDP data
Evolve shareholders demand answers

IRG See IRG research reports